We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Following its Phase 1 investigation, the CMA has found that Theramex's proposed purchase of Femoston and Duphaston could reduce competition and choice for hormone replacement therapy treatments.
Half a million women in England have accessed cheaper HRT - the main treatment for negative menopause symptoms - since last April.
MHRA review of levothyroxine products in response to concerns about potential inconsistencies of different products.
This series brings together work to develop specific evidence-based scientific advice to address the needs of industry and regulators.
These reports explain our assessment of the scientific evidence used to lead to regulatory decisions on the safety of medicines or medicines classes.
Details of the suspension of the marketing authorisation of Levothyroxine 100 microgram tablets, including MHRA investigations.
Volume 44 of the non-technical summaries granted under the Animals (Scientific Procedures) Act 1986 during 2013.
Volume 22 of the non-technical summaries granted under the Animals (Scientific Procedures) Act 1986 during 2013.
The Medicines and Healthcare products Regulatory Agency (MHRA) has today (7 March 2024) approved the medicine rozanolixizumab (Rystiggo) to treat adults with generalised myasthenia gravis, an autoimmune disease that causes muscle weakness, which can affect multiple muscle groups throughout the...
This template is used to notify GPs of a suspected positive newborn blood spot screening result of congenital hypothyroidism (CHT).
Guidance on the referral and management of babies with congenital hypothyroidism (CHT).
Volume 53 of the non-technical summaries granted under the Animals (Scientific Procedures) Act 1986 during 2013.
If a patient reports persistent symptoms when switching between different levothyroxine tablet formulations, consider consistently prescribing a specific product known to be well tolerated by the patient. If symptoms or poor control of thyroid function persist (despite adhering to a...
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).